Second booster dose offers additional protection against post COVID-19 sequelae

13 hours ago
Jairia Dela Cruz
Jairia Dela CruzSenior Medical Writer; MIMS
Jairia Dela Cruz
Jairia Dela Cruz Senior Medical Writer; MIMS
Second booster dose offers additional protection against post COVID-19 sequelae

Individuals who have received four doses of the COVID-19 vaccine have a lower risk of post COVID-19 condition compared with those who have received only three doses, according to an observational study.

In a propensity score-matched cohort of adults, the incidence rate of post COVID-19 condition was 1.14 per 1,000 person-years in the four-dose group vs 1.67 per 1,000 person-years in the three-dose group, reported first author Dr Lisa Morris from the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, and colleagues. [EClinicalMedicine 2026;doi:10.1016/j.eclinm.2026.104215]

Compared with three doses, four doses were associated with a 31-percent reduction in the risk of a post COVID-19 condition diagnosis (hazard ratio, 0.69, 95 percent confidence interval, 0.62–0.78), with a vaccine effectiveness of 31 percent (95 percent CI, 22–38).

“The protective effect [of a second booster dose] against post COVID-19 condition was observed in individuals both with and without risk factors for severe acute COVID-19, with higher effect in the at-risk group and lower effect in the group without risk factors,” Morris and colleagues noted.

The incidence rates of post COVID-19 condition were 1.32 per 1,000 person-years in the four-dose group vs 2.14 per 1,000 person-years in the three-dose group among individuals with risk factors for severe acute COVID-19 and 0.98 vs 1.20 per 1,000 person-years among those who had no risk factors.

The vaccine effectiveness of a second booster dose against post COVID-19 condition was 38 percent and 18 percent for individuals with risk factors and those without risk factors, respectively.

“Our findings of a protective effect against post COVID-19 condition add to the evidence of the effectiveness of the COVID-19 vaccines regarding prolonged effects from the infection,” Morris and colleagues said.

“These positive effects from the COVID-19 vaccines could be taken into account when planning vaccination strategies for individuals,” they added.

For the study, the authors used data from the Swedish COVID-19 Investigation for Future Insights—a Population Epidemiology Approach using Register Linkage (SCIFI-PEARL) project. The analysis included 801,869 individuals who received a second booster dose and 801,869 individuals who received a first booster dose, matched according to propensity scores.

Individuals with risk factors included those who were ≥65 years of age, living in a nursing home or special facility for the elderly, having home care services, pregnant, presenting with comorbidities including diabetes, cardiovascular disease, chronic respiratory disease, obesity diagnosis, liver disease, renal failure, Down’s syndrome, neuromuscular disease, or immunodeficiency due to medication or underlying disease.

“Although the pandemic phase has passed, SARS-CoV-2 continues to circulate in society… As long as SARS-CoV-2 circulates in society, individuals are at risk of developing acute infection and potentially post COVID-19 condition,” Morris and colleagues said.

“Reinfections still have an impact on health outcomes, in both the acute and postacute phase… Therefore, evaluating vaccine effectiveness and appropriate targeting of preventive measures against COVID-19 and post COVID-19 condition remains important,” they added.

The authors highlighted a need for additional research on the potential beneficial effects of the vaccines against prolonged symptoms in other contexts and using different measures of post COVID-19 condition.